US FDA declines to approve Regenxbio's rare disease drug
09/02/2026 21:11
Feb 9 (Reuters) - Regenxbio RGNX.O said on Monday the U.S. Food and Drug Administration has declined to approve its drug for a rare disease. (Reporting by Sneha S K; Editing by Alan Barona) ((Sneha.SK@thomsonreuters.com;))
Recent news on REGENXBIO
See all newsBrief: Regenxbio says Sarepta To Pay $39 Million To Regenxbio Within 10 Days Of Effective Date
Regenxbio climbs as new director buys nearly $1 million of stock
Brief: Regenxbio Strengthens Board Of Directors With Appointment Of Greg Ciongoli
U.S. STOCKS ON THE MOVE-Strategy, Ecovyst, Azenta
U.S. STOCKS ON THE MOVE-Azenta, Qiagen NV, Capricor Therapeutics